p-fgfr1 antibody Search Results


bi- phospho-fgfr y653/654 (pfgfr1  (WuXi AppTec)
90
WuXi AppTec bi- phospho-fgfr y653/654 (pfgfr1
“Control” indicates untreated conceptuses that were cultured alongside pharmacologically-treated ones until 7–8s stage. Transverse histological sections (F-I, M, N, T-V) are oriented with ventral toward the bottom. Black asterisk indicates the VOC (A, C, D, F, H, M, O, Q, R, T, U). (A-D, O-R) 3D models, in side view (posterior to the right), reconstructed from post-culture PECAM-1-immunostained arterial vessels at the posterior embryonic-extraembryonic interface of control (A, O), PD173074-treated (B-D) or chlorate-treated (P-R) conceptuses (initial stages, upper right). Color key as in Fig. 2. Black arrows indicate missing arterial connections due to loss of the VOC (B, P) or to incomplete branching of the VOC (C, Q). (E, S) Frequency of anomalies observed in the vascular confluence in post-culture specimens from PD173074 (E) or chlorate (S) experiments by their initial stage, sample size and group’s treatment (± PD173074 or chlorate). (F, G) Transverse sections in the flk-1: lacZ reporter showing the PECAM-1-positive endothelialized VOC in the control (F), but non-endothelialized angioblasts in the prospective VOC of PD173074-treated specimens (G, white arrow). (H, I) Transverse sections in the flk-1: lacZ reporter showing down-regulation of T in the endothelialized control VOC (H) and in nonendothelialized angioblasts of the prospective VOC in PD173074-treated specimens (white arrow) (I). (J-L) Histological sections through the prospective VOC showing that <t>pFGFR1</t> is unaffected in the three TC genotypes. (M, N) Transverse sections in the flk-1: lacZ reporter showing down-regulation of OCT-3/4 in the endothelialized VOC of untreated controls (M) and in non-endothelialized angioblasts of the prospective VOC in PD173074-treated specimens (N, white arrow). (T-V) Transverse histological sections showing the PECAM-1-positive endothelialized VOC in a control (T) and a chlorate-treated specimen (U), and non-endothelialized angioblasts in the prospective VOC of another chlorate-treated specimen (V, white arrow). Scale bar (V): 6 μm (J-L); 25 μm (F-I, M, N, T-V). al, allantois; da, dorsal aortae; omphalomesenteric artery, oa; umbilical artery; ys, yolk sac.
Bi Phospho Fgfr Y653/654 (Pfgfr1, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-fgfr1+antibody/pmc05760991-100-12-17?v=WuXi+AppTec
Average 90 stars, based on 1 article reviews
bi- phospho-fgfr y653/654 (pfgfr1 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
fgfr1 [p tyr651, p tyr652] antibody  (Bio-Techne corporation)
90
Bio-Techne corporation fgfr1 [p tyr651, p tyr652] antibody
“Control” indicates untreated conceptuses that were cultured alongside pharmacologically-treated ones until 7–8s stage. Transverse histological sections (F-I, M, N, T-V) are oriented with ventral toward the bottom. Black asterisk indicates the VOC (A, C, D, F, H, M, O, Q, R, T, U). (A-D, O-R) 3D models, in side view (posterior to the right), reconstructed from post-culture PECAM-1-immunostained arterial vessels at the posterior embryonic-extraembryonic interface of control (A, O), PD173074-treated (B-D) or chlorate-treated (P-R) conceptuses (initial stages, upper right). Color key as in Fig. 2. Black arrows indicate missing arterial connections due to loss of the VOC (B, P) or to incomplete branching of the VOC (C, Q). (E, S) Frequency of anomalies observed in the vascular confluence in post-culture specimens from PD173074 (E) or chlorate (S) experiments by their initial stage, sample size and group’s treatment (± PD173074 or chlorate). (F, G) Transverse sections in the flk-1: lacZ reporter showing the PECAM-1-positive endothelialized VOC in the control (F), but non-endothelialized angioblasts in the prospective VOC of PD173074-treated specimens (G, white arrow). (H, I) Transverse sections in the flk-1: lacZ reporter showing down-regulation of T in the endothelialized control VOC (H) and in nonendothelialized angioblasts of the prospective VOC in PD173074-treated specimens (white arrow) (I). (J-L) Histological sections through the prospective VOC showing that <t>pFGFR1</t> is unaffected in the three TC genotypes. (M, N) Transverse sections in the flk-1: lacZ reporter showing down-regulation of OCT-3/4 in the endothelialized VOC of untreated controls (M) and in non-endothelialized angioblasts of the prospective VOC in PD173074-treated specimens (N, white arrow). (T-V) Transverse histological sections showing the PECAM-1-positive endothelialized VOC in a control (T) and a chlorate-treated specimen (U), and non-endothelialized angioblasts in the prospective VOC of another chlorate-treated specimen (V, white arrow). Scale bar (V): 6 μm (J-L); 25 μm (F-I, M, N, T-V). al, allantois; da, dorsal aortae; omphalomesenteric artery, oa; umbilical artery; ys, yolk sac.
Fgfr1 [P Tyr651, P Tyr652] Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-fgfr1+antibody/bio-techne+corporation___nbp2-24462?v=Bio-Techne+corporation
Average 90 stars, based on 1 article reviews
fgfr1 [p tyr651, p tyr652] antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
p-fgfr1 antibody  (RayBiotech inc)
90
RayBiotech inc p-fgfr1 antibody
“Control” indicates untreated conceptuses that were cultured alongside pharmacologically-treated ones until 7–8s stage. Transverse histological sections (F-I, M, N, T-V) are oriented with ventral toward the bottom. Black asterisk indicates the VOC (A, C, D, F, H, M, O, Q, R, T, U). (A-D, O-R) 3D models, in side view (posterior to the right), reconstructed from post-culture PECAM-1-immunostained arterial vessels at the posterior embryonic-extraembryonic interface of control (A, O), PD173074-treated (B-D) or chlorate-treated (P-R) conceptuses (initial stages, upper right). Color key as in Fig. 2. Black arrows indicate missing arterial connections due to loss of the VOC (B, P) or to incomplete branching of the VOC (C, Q). (E, S) Frequency of anomalies observed in the vascular confluence in post-culture specimens from PD173074 (E) or chlorate (S) experiments by their initial stage, sample size and group’s treatment (± PD173074 or chlorate). (F, G) Transverse sections in the flk-1: lacZ reporter showing the PECAM-1-positive endothelialized VOC in the control (F), but non-endothelialized angioblasts in the prospective VOC of PD173074-treated specimens (G, white arrow). (H, I) Transverse sections in the flk-1: lacZ reporter showing down-regulation of T in the endothelialized control VOC (H) and in nonendothelialized angioblasts of the prospective VOC in PD173074-treated specimens (white arrow) (I). (J-L) Histological sections through the prospective VOC showing that <t>pFGFR1</t> is unaffected in the three TC genotypes. (M, N) Transverse sections in the flk-1: lacZ reporter showing down-regulation of OCT-3/4 in the endothelialized VOC of untreated controls (M) and in non-endothelialized angioblasts of the prospective VOC in PD173074-treated specimens (N, white arrow). (T-V) Transverse histological sections showing the PECAM-1-positive endothelialized VOC in a control (T) and a chlorate-treated specimen (U), and non-endothelialized angioblasts in the prospective VOC of another chlorate-treated specimen (V, white arrow). Scale bar (V): 6 μm (J-L); 25 μm (F-I, M, N, T-V). al, allantois; da, dorsal aortae; omphalomesenteric artery, oa; umbilical artery; ys, yolk sac.
P Fgfr1 Antibody, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-fgfr1+antibody/pm32278061-74-6-11?v=RayBiotech+inc
Average 90 stars, based on 1 article reviews
p-fgfr1 antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


“Control” indicates untreated conceptuses that were cultured alongside pharmacologically-treated ones until 7–8s stage. Transverse histological sections (F-I, M, N, T-V) are oriented with ventral toward the bottom. Black asterisk indicates the VOC (A, C, D, F, H, M, O, Q, R, T, U). (A-D, O-R) 3D models, in side view (posterior to the right), reconstructed from post-culture PECAM-1-immunostained arterial vessels at the posterior embryonic-extraembryonic interface of control (A, O), PD173074-treated (B-D) or chlorate-treated (P-R) conceptuses (initial stages, upper right). Color key as in Fig. 2. Black arrows indicate missing arterial connections due to loss of the VOC (B, P) or to incomplete branching of the VOC (C, Q). (E, S) Frequency of anomalies observed in the vascular confluence in post-culture specimens from PD173074 (E) or chlorate (S) experiments by their initial stage, sample size and group’s treatment (± PD173074 or chlorate). (F, G) Transverse sections in the flk-1: lacZ reporter showing the PECAM-1-positive endothelialized VOC in the control (F), but non-endothelialized angioblasts in the prospective VOC of PD173074-treated specimens (G, white arrow). (H, I) Transverse sections in the flk-1: lacZ reporter showing down-regulation of T in the endothelialized control VOC (H) and in nonendothelialized angioblasts of the prospective VOC in PD173074-treated specimens (white arrow) (I). (J-L) Histological sections through the prospective VOC showing that pFGFR1 is unaffected in the three TC genotypes. (M, N) Transverse sections in the flk-1: lacZ reporter showing down-regulation of OCT-3/4 in the endothelialized VOC of untreated controls (M) and in non-endothelialized angioblasts of the prospective VOC in PD173074-treated specimens (N, white arrow). (T-V) Transverse histological sections showing the PECAM-1-positive endothelialized VOC in a control (T) and a chlorate-treated specimen (U), and non-endothelialized angioblasts in the prospective VOC of another chlorate-treated specimen (V, white arrow). Scale bar (V): 6 μm (J-L); 25 μm (F-I, M, N, T-V). al, allantois; da, dorsal aortae; omphalomesenteric artery, oa; umbilical artery; ys, yolk sac.

Journal: Developmental biology

Article Title: Brachyury drives formation of a distinct vascular branchpoint critical for fetal-placental arterial union in the mouse gastrula

doi: 10.1016/j.ydbio.2017.03.032

Figure Lengend Snippet: “Control” indicates untreated conceptuses that were cultured alongside pharmacologically-treated ones until 7–8s stage. Transverse histological sections (F-I, M, N, T-V) are oriented with ventral toward the bottom. Black asterisk indicates the VOC (A, C, D, F, H, M, O, Q, R, T, U). (A-D, O-R) 3D models, in side view (posterior to the right), reconstructed from post-culture PECAM-1-immunostained arterial vessels at the posterior embryonic-extraembryonic interface of control (A, O), PD173074-treated (B-D) or chlorate-treated (P-R) conceptuses (initial stages, upper right). Color key as in Fig. 2. Black arrows indicate missing arterial connections due to loss of the VOC (B, P) or to incomplete branching of the VOC (C, Q). (E, S) Frequency of anomalies observed in the vascular confluence in post-culture specimens from PD173074 (E) or chlorate (S) experiments by their initial stage, sample size and group’s treatment (± PD173074 or chlorate). (F, G) Transverse sections in the flk-1: lacZ reporter showing the PECAM-1-positive endothelialized VOC in the control (F), but non-endothelialized angioblasts in the prospective VOC of PD173074-treated specimens (G, white arrow). (H, I) Transverse sections in the flk-1: lacZ reporter showing down-regulation of T in the endothelialized control VOC (H) and in nonendothelialized angioblasts of the prospective VOC in PD173074-treated specimens (white arrow) (I). (J-L) Histological sections through the prospective VOC showing that pFGFR1 is unaffected in the three TC genotypes. (M, N) Transverse sections in the flk-1: lacZ reporter showing down-regulation of OCT-3/4 in the endothelialized VOC of untreated controls (M) and in non-endothelialized angioblasts of the prospective VOC in PD173074-treated specimens (N, white arrow). (T-V) Transverse histological sections showing the PECAM-1-positive endothelialized VOC in a control (T) and a chlorate-treated specimen (U), and non-endothelialized angioblasts in the prospective VOC of another chlorate-treated specimen (V, white arrow). Scale bar (V): 6 μm (J-L); 25 μm (F-I, M, N, T-V). al, allantois; da, dorsal aortae; omphalomesenteric artery, oa; umbilical artery; ys, yolk sac.

Article Snippet: Primary antibodies, sources, stock concentrations, dilutions, and Research Resource Identifiers (RRIDs) were: Bi- Phospho-FGFR Y653/654 (pFGFR1) (AP3104A, Abgent, San Diego, CA; 0.25 mg/ml, rabbit polyclonal; 1/60 dilution; RRID: AB_ 636986); BRACHYURY (T) (sc-17743, Santa Cruz Biotechnologies, Santa Cruz, California; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_634980); CASPASE-3 (CASP3) (559565, BD Biosciences, San Jose, California; 0.5 mg/ml, rabbit monoclonal; 1/100 dilution; RRID: AB_397274); FGF2 (sc-79-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_631498); FGFR1 (ab10646, Abcam, Cambridge, MA; 1500 μg/ml, rabbit polyclonal; 1/400 dilution; RRID: AB_297367); FGFR2 (sc-122-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution; RRID: AB_631510); FGFR3 (sc-123-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution); FLK-1 (sc-315-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_632599) ( Inman and Downs, 2006b ); OCT-3/4 (sc-8628, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_653551); and PECAM-1 (AF3628, R & D Systems, Minneapolis, MN; 0.2 mg/ml, goat polyclonal; 1/500 dilution; RRID: AB_2161028).

Techniques: Cell Culture

(A-G) Immunostaining for FGFR3 (A), FGFR2 (B), FGFR1 (C), FGF2 (D), all at the headfold stages, and pFGFR1 (E-G) in EB through 4s stage flk-1: lacZ reporter specimens. Boxed region in main panels is the prospective VOC (A-E) or endothelialized VOC (F, G) region, enlarged in insets, lower left. Dashed outline, posteriormost (distalmost) extension of the primitive streak, and white asterisk, ACD (A-D, F, G). Red arrowheads (A, B), FGFR-3- and FGFR-2-negative cells. Black arrowhead (C), FGFR1-positive rosette. Black arrowhead (D), FGF2-positive cell. Black arrowheads (E, F), flk-1-positive/pFGFR1-positive angioblasts. Black asterisk (G), flk-1-positive/pFGFR1-negative mature VOC. (H-K) EHF stage, frontal (ventral) optical section through ventral allantoic and embryonic tissue stained with DAPI (H), T (I), pFGFR1 (J); channels merged (K). Insets are enlargements of prospective VOC, boxed in main panels. White arrowhead, T-positive/pFGFR1-positive angioblast; red arrowhead, pFGFR1-positive/T-negative angioblast. Scale bar (G): 20 μm (A-K). al, allantois; am, amnion; ch, chorion; em, embryo; ua, umbilical artery; ys, yolk sac.

Journal: Developmental biology

Article Title: Brachyury drives formation of a distinct vascular branchpoint critical for fetal-placental arterial union in the mouse gastrula

doi: 10.1016/j.ydbio.2017.03.032

Figure Lengend Snippet: (A-G) Immunostaining for FGFR3 (A), FGFR2 (B), FGFR1 (C), FGF2 (D), all at the headfold stages, and pFGFR1 (E-G) in EB through 4s stage flk-1: lacZ reporter specimens. Boxed region in main panels is the prospective VOC (A-E) or endothelialized VOC (F, G) region, enlarged in insets, lower left. Dashed outline, posteriormost (distalmost) extension of the primitive streak, and white asterisk, ACD (A-D, F, G). Red arrowheads (A, B), FGFR-3- and FGFR-2-negative cells. Black arrowhead (C), FGFR1-positive rosette. Black arrowhead (D), FGF2-positive cell. Black arrowheads (E, F), flk-1-positive/pFGFR1-positive angioblasts. Black asterisk (G), flk-1-positive/pFGFR1-negative mature VOC. (H-K) EHF stage, frontal (ventral) optical section through ventral allantoic and embryonic tissue stained with DAPI (H), T (I), pFGFR1 (J); channels merged (K). Insets are enlargements of prospective VOC, boxed in main panels. White arrowhead, T-positive/pFGFR1-positive angioblast; red arrowhead, pFGFR1-positive/T-negative angioblast. Scale bar (G): 20 μm (A-K). al, allantois; am, amnion; ch, chorion; em, embryo; ua, umbilical artery; ys, yolk sac.

Article Snippet: Primary antibodies, sources, stock concentrations, dilutions, and Research Resource Identifiers (RRIDs) were: Bi- Phospho-FGFR Y653/654 (pFGFR1) (AP3104A, Abgent, San Diego, CA; 0.25 mg/ml, rabbit polyclonal; 1/60 dilution; RRID: AB_ 636986); BRACHYURY (T) (sc-17743, Santa Cruz Biotechnologies, Santa Cruz, California; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_634980); CASPASE-3 (CASP3) (559565, BD Biosciences, San Jose, California; 0.5 mg/ml, rabbit monoclonal; 1/100 dilution; RRID: AB_397274); FGF2 (sc-79-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_631498); FGFR1 (ab10646, Abcam, Cambridge, MA; 1500 μg/ml, rabbit polyclonal; 1/400 dilution; RRID: AB_297367); FGFR2 (sc-122-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution; RRID: AB_631510); FGFR3 (sc-123-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution); FLK-1 (sc-315-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_632599) ( Inman and Downs, 2006b ); OCT-3/4 (sc-8628, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_653551); and PECAM-1 (AF3628, R & D Systems, Minneapolis, MN; 0.2 mg/ml, goat polyclonal; 1/500 dilution; RRID: AB_2161028).

Techniques: Immunostaining, Staining

Schematics in A-C are depicted entirely through the midsagittal plane, while the embryonic component in D, E is slightly lateral, to visualize one of the paired dorsal aortae. (A) As the allantoic bud (al) emerges (~E7.25), the T-positive primitive streak (dashed outline) has extended into the extraembryonic region, positioning the allantoic-yolk sac junction (arrows), where prospective VOC angioblasts (colored ovals) exhibit flk-1 (light blue), pFGFR1 and T (alternating brown and pink, respectively). T-dosage, i.e., the number of normal copies of T present, regulates extension of the primitive streak and thus, correct axial placement of the allantoic-yolk sac junction according to TC genotype (arrows) along the anteroposterior axis. (B) As the al elongates (~E7.75), the streak (dashed outline) expands into the ACD (red asterisk), where it ensures that the prospective VOC angioblasts (colored ovals), which are now beginning to lose T (pink), are organized to the midline. (C) By 2s (~E8.25), angioblasts have endothelialized (light blue flattenedovals) as a result of FGFR1 signaling to form the VOC (red, black asterisk), which now lacks both T (pink) and pFGFR1 (brown). (D) By 6–8s (~E8.5), the primitive streak (dashed outline)/ACD (red asterisk) regresses (Downs et al., 2009), and the VOC (red, black asterisk) branches as a result of pFGFR1 signaling to unite, in sequential order (red numbers), the omphalomesenteric artery (purple; 1), umbilical artery (yellow; 2), and dorsal aortae (dark blue; 3) to create the OUA connection. (E) Anterior movements during embryonic turning (11s, ~E9.0) cause the VOC (red, black asterisk) to curve around the hindgut (hg), creating the medial umbilical roots (mur). (F) Later, during the early-to-mid fetal period (~E13.5), the mur begin to regress, allowing the lateral umbilical roots (lur, dark blue; derived from the dorsal aortae) to assume prominence, connecting to the umbilical artery (yellow) at the VOC branchpoint (red, black asterisk). am, amnion; ch, chorion; em, embryo; ys, yolk sac.

Journal: Developmental biology

Article Title: Brachyury drives formation of a distinct vascular branchpoint critical for fetal-placental arterial union in the mouse gastrula

doi: 10.1016/j.ydbio.2017.03.032

Figure Lengend Snippet: Schematics in A-C are depicted entirely through the midsagittal plane, while the embryonic component in D, E is slightly lateral, to visualize one of the paired dorsal aortae. (A) As the allantoic bud (al) emerges (~E7.25), the T-positive primitive streak (dashed outline) has extended into the extraembryonic region, positioning the allantoic-yolk sac junction (arrows), where prospective VOC angioblasts (colored ovals) exhibit flk-1 (light blue), pFGFR1 and T (alternating brown and pink, respectively). T-dosage, i.e., the number of normal copies of T present, regulates extension of the primitive streak and thus, correct axial placement of the allantoic-yolk sac junction according to TC genotype (arrows) along the anteroposterior axis. (B) As the al elongates (~E7.75), the streak (dashed outline) expands into the ACD (red asterisk), where it ensures that the prospective VOC angioblasts (colored ovals), which are now beginning to lose T (pink), are organized to the midline. (C) By 2s (~E8.25), angioblasts have endothelialized (light blue flattenedovals) as a result of FGFR1 signaling to form the VOC (red, black asterisk), which now lacks both T (pink) and pFGFR1 (brown). (D) By 6–8s (~E8.5), the primitive streak (dashed outline)/ACD (red asterisk) regresses (Downs et al., 2009), and the VOC (red, black asterisk) branches as a result of pFGFR1 signaling to unite, in sequential order (red numbers), the omphalomesenteric artery (purple; 1), umbilical artery (yellow; 2), and dorsal aortae (dark blue; 3) to create the OUA connection. (E) Anterior movements during embryonic turning (11s, ~E9.0) cause the VOC (red, black asterisk) to curve around the hindgut (hg), creating the medial umbilical roots (mur). (F) Later, during the early-to-mid fetal period (~E13.5), the mur begin to regress, allowing the lateral umbilical roots (lur, dark blue; derived from the dorsal aortae) to assume prominence, connecting to the umbilical artery (yellow) at the VOC branchpoint (red, black asterisk). am, amnion; ch, chorion; em, embryo; ys, yolk sac.

Article Snippet: Primary antibodies, sources, stock concentrations, dilutions, and Research Resource Identifiers (RRIDs) were: Bi- Phospho-FGFR Y653/654 (pFGFR1) (AP3104A, Abgent, San Diego, CA; 0.25 mg/ml, rabbit polyclonal; 1/60 dilution; RRID: AB_ 636986); BRACHYURY (T) (sc-17743, Santa Cruz Biotechnologies, Santa Cruz, California; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_634980); CASPASE-3 (CASP3) (559565, BD Biosciences, San Jose, California; 0.5 mg/ml, rabbit monoclonal; 1/100 dilution; RRID: AB_397274); FGF2 (sc-79-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_631498); FGFR1 (ab10646, Abcam, Cambridge, MA; 1500 μg/ml, rabbit polyclonal; 1/400 dilution; RRID: AB_297367); FGFR2 (sc-122-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution; RRID: AB_631510); FGFR3 (sc-123-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/300 dilution); FLK-1 (sc-315-G, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/50 dilution; RRID: AB_632599) ( Inman and Downs, 2006b ); OCT-3/4 (sc-8628, Santa Cruz Biotechnologies; 200 μg/ml, goat polyclonal; 1/100 dilution; RRID: AB_653551); and PECAM-1 (AF3628, R & D Systems, Minneapolis, MN; 0.2 mg/ml, goat polyclonal; 1/500 dilution; RRID: AB_2161028).

Techniques: Derivative Assay